| Non-coding RNAs in cancer: Platforms and strategies for investigating the genomic “dark matter” K Grillone, C Riillo, F Scionti, R Rocca, G Tradigo, PH Guzzi, S Alcaro, ... Journal of Experimental & Clinical Cancer Research 39, 1-19, 2020 | 208 | 2020 |
| Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma C Perez, C Botta, A Zabaleta, N Puig, MT Cedena, I Goicoechea, ... Blood, The Journal of the American Society of Hematology 136 (2), 199-209, 2020 | 110 | 2020 |
| miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review MT Di Martino, M Arbitrio, D Caracciolo, A Cordua, O Cuomo, K Grillone, ... Molecular Therapy-Nucleic Acids 27, 1191-1224, 2022 | 93 | 2022 |
| miRNAs and lncRNAs as novel therapeutic targets to improve cancer immunotherapy MT Di Martino, C Riillo, F Scionti, K Grillone, N Polerà, D Caracciolo, ... Cancers 13 (7), 1587, 2021 | 68 | 2021 |
| MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells C Botta, M Cucè, MR Pitari, D Caracciolo, A Gulla, E Morelli, C Riillo, ... Leukemia 32 (4), 1003-1015, 2018 | 65 | 2018 |
| Alternative non-homologous end-joining: error-prone DNA repair as cancer’s achilles’ heel D Caracciolo, C Riillo, MT Di Martino, P Tagliaferri, P Tassone Cancers 13 (6), 1392, 2021 | 54 | 2021 |
| miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma M Rossi, E Altomare, C Botta, ME Gallo Cantafio, S Sarvide, D Caracciolo, ... Leukemia 35 (3), 823-834, 2021 | 47 | 2021 |
| Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma D Caracciolo, F Scionti, G Juli, E Altomare, G Golino, K Todoerti, ... Haematologica 106 (1), 185, 2020 | 43 | 2020 |
| Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma M Cucè, ME Gallo Cantafio, MA Siciliano, C Riillo, D Caracciolo, F Scionti, ... Journal of hematology & oncology 12, 1-17, 2019 | 39 | 2019 |
| Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis MA Siciliano, G Caridà, D Ciliberto, M d’Apolito, C Pelaia, D Caracciolo, ... ESMO open 7 (3), 100465, 2022 | 33 | 2022 |
| The new microtubule-targeting agent SIX2G induces immunogenic cell death in multiple myeloma K Grillone, C Riillo, R Rocca, S Ascrizzi, V Spanò, F Scionti, N Polerà, ... International Journal of Molecular Sciences 23 (18), 10222, 2022 | 31 | 2022 |
| Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label … P Tassone, MT Di Martino, M Arbitrio, L Fiorillo, N Staropoli, D Ciliberto, ... Journal of hematology & oncology 16 (1), 68, 2023 | 28 | 2023 |
| Raman spectroscopic stratification of multiple myeloma patients based on exosome profiling M Russo, L Tirinato, F Scionti, ML Coluccio, G Perozziello, C Riillo, ... ACS omega 5 (47), 30436-30443, 2020 | 28 | 2020 |
| miR-22 modulates lenalidomide activity by counteracting MYC addiction in multiple myeloma D Caracciolo, C Riillo, G Juli, F Scionti, K Todoerti, N Polerà, K Grillone, ... Cancers 13 (17), 4365, 2021 | 21 | 2021 |
| The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives D Caracciolo, A Mancuso, N Polerà, C Froio, G D’Aquino, C Riillo, ... Experimental Hematology & Oncology 12 (1), 5, 2023 | 19 | 2023 |
| Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia D Caracciolo, C Riillo, A Ballerini, G Gaipa, L Lhermitte, M Rossi, C Botta, ... Journal for immunotherapy of cancer 9 (2), e002026, 2021 | 18 | 2021 |
| Error‐prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment D Caracciolo, C Riillo, M Arbitrio, MT Di Martino, P Tagliaferri, P Tassone International journal of cancer 147 (10), 2658-2668, 2020 | 17 | 2020 |
| TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma F Scionti, G Juli, R Rocca, N Polerà, M Nadai, K Grillone, D Caracciolo, ... Journal of Experimental & Clinical Cancer Research 42 (1), 71, 2023 | 13 | 2023 |
| Risk alleles for multiple myeloma susceptibility in ADME genes F Scionti, G Agapito, D Caracciolo, C Riillo, K Grillone, M Cannataro, ... Cells 11 (2), 189, 2022 | 13 | 2022 |
| A novel bispecific T-cell engager (CD1a x CD3ε) BTCE is effective against cortical-derived T cell acute lymphoblastic leukemia (T-ALL) cells C Riillo, D Caracciolo, K Grillone, N Polerà, FM Tuccillo, P Bonelli, G Juli, ... Cancers 14 (12), 2886, 2022 | 12 | 2022 |
